Topokine Therapeutics, a Boston, MA-based clinical-stage biotechnology company developing topical medications for non-invasive contouring of the face and body, received a new round of venture financing from Schooner Capital.
The amount of the transaction was not disclosed.
The company intends to use the funds to advance its clinical pipeline and expand its worldwide intellectual property position.
Led by Murat Kalayoglu, MD, PhD, President and CEO, Topokine is advancing its lead program, XAF5 Gel, a topical adipomodulatory product in Phase 2 clinical development for local reduction of excess submental fat (“double chin”) and other indications.
Its pipeline also includes XOPH5 Ointment to treat steatoblepharon (“eye bags”) and TAT4, a topical “filler” therapy to increase local tissue volume.